Bridgepoint agrees majority investment in German testing group GBA

Bridgepoint has agreed to acquire a majority stake in GBA Group, a Hamburg-based laboratory testing company, PE Hub reported. The transaction shifts control of a testing business serving environmental, food, pharmaceuticals, medical device and cosmetics customers.

Ardian will sell the vast majority of its holding as part of the deal, while GBA’s management will remain invested, according to PE Hub. Financial terms were not included in PE Hub’s report.

The structure gives Bridgepoint a controlling position in the company while leaving existing executives with an economic interest in the business. In private equity transactions, management reinvestment is often used to keep senior leadership aligned with the new owner’s commercial plan, although PE Hub did not provide details of the size or terms of GBA management’s continuing stake.

Testing platform expands Bridgepoint’s TIC exposure

GBA operates in laboratory testing, providing services across regulated and technical end markets, PE Hub reported. Its areas of work include environmental testing, food testing, pharmaceuticals, medical devices and cosmetics.

Those activities sit within the broader testing, inspection and certification field, often referred to as TIC. Companies in the sector typically provide independent testing or verification services to help clients meet product, safety, quality or regulatory requirements. PE Hub reported that Bridgepoint has previously backed ten TIC platforms, including Element Materials Technology and LGC.

The GBA transaction therefore adds another asset in a field where Bridgepoint has prior investment experience. PE Hub did not report a closing date, financing details, regulatory conditions or valuation for the planned acquisition.

Ardian reduces position

Ardian’s role in the transaction is as the selling shareholder, with the firm set to exit most of its investment in GBA, according to PE Hub. The report did not state whether Ardian will retain any residual interest after completion, beyond saying it will sell the vast majority of its stake.

Management continuity is also part of the deal as described by PE Hub. GBA’s leadership will remain invested alongside Bridgepoint, leaving the operating team with continuing exposure to the company after the change in majority ownership.

The reported agreement underscores continuing private equity activity in specialist business services, where laboratory testing providers can serve multiple regulated markets. For Bridgepoint, the deal adds a German-headquartered platform to a portfolio history that PE Hub said already includes several TIC investments.

This story draws on original reporting from PE Hub.